Illustrative image.
KADCYLA
Trastuzumab Emtansine
$3070.00
100mg · 1 vial
BrandBranded medicine· By Roche
Strength
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Ships cold, in insulated packing
This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
100mg
160mg
FDA boxed warningHepatotoxicity, cardiac toxicity, embryo-fetal toxicity
Hepatotoxicity: Serious hepatotoxicity has been reported, including liver failure and death in patients treated with KADCYLA. Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases or total bilirubin.
Cardiac Toxicity: KADCYLA administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA. Withhold treatment for clinically significant decrease in left ventricular function.
Embryo-Fetal Toxicity: Exposure to KADCYLA during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
Hepatotoxicity, liver failure and death have occurred in KADCYLA-treated patients. Monitor hepatic function prior to initiation and prior to each dose. Institute dose modifications or permanently discontinue as appropriate.
KADCYLA may lead to reductions in left ventricular ejection fraction (LVEF). Assess LVEF prior to initiation. Monitor and withhold dosing or discontinue as appropriate.
About KADCYLA
Overview
KADCYLA (ado-trastuzumab emtansine) is a prescription medicine that links a HER2-targeting antibody to a cancer-cell-killing drug. It is used alone for HER2-positive breast cancer that has spread after prior trastuzumab and taxane treatment, when patients have received treatment for metastatic disease or the cancer returned during or within six months of completing treatment given after surgery. It is also used after surgery for HER2-positive early breast cancer when invasive cancer remains after taxane- and trastuzumab-based treatment given before surgery. It works by attaching to HER2 on cancer cells and releasing a drug inside them that disrupts cell division and causes cell death.
What it treats
- HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, separately or together, when patients have received prior treatment for metastatic disease or the cancer returned during or within six months of completing treatment after surgery. - HER2-positive early breast cancer with invasive cancer remaining after taxane- and trastuzumab-based treatment before surgery, for treatment after surgery. KADCYLA is used on its own. Patients are selected using an FDA-authorized test for KADCYLA.
Safety information
Side effects
Common side effects of KADCYLA include tiredness, nausea, muscle and bone pain, headache, bleeding, low platelet counts and increased liver enzyme levels. Constipation and nosebleeds are also common in patients treated for metastatic breast cancer. Peripheral nerve problems and joint pain are also common in patients treated for early breast cancer. Serious side effects that warrant contacting a doctor include liver damage, reduced heart pumping function, lung inflammation, infusion-related or allergic reactions, bleeding, low platelet counts and nerve damage. Bleeding can be fatal, including in people with no known risk factors. Blood-thinning and antiplatelet medicines require caution and may require additional monitoring. Patients are monitored during and after the infusion for reactions, and platelet counts are checked before each treatment. Serious reactions may require treatment to be paused or stopped. KADCYLA can also harm an unborn baby; contact your doctor if you are pregnant or think you may be pregnant.
FDA boxed warning
Hepatotoxicity, cardiac toxicity, embryo-fetal toxicity
Hepatotoxicity: Serious hepatotoxicity has been reported, including liver failure and death in patients treated with KADCYLA. Monitor serum transaminases and bilirubin prior to initiation of KADCYLA treatment and prior to each KADCYLA dose. Reduce dose or discontinue KADCYLA as appropriate in cases of increased serum transaminases or total bilirubin.
Cardiac Toxicity: KADCYLA administration may lead to reductions in left ventricular ejection fraction (LVEF). Evaluate left ventricular function in all patients prior to and during treatment with KADCYLA. Withhold treatment for clinically significant decrease in left ventricular function.
Embryo-Fetal Toxicity: Exposure to KADCYLA during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
Hepatotoxicity, liver failure and death have occurred in KADCYLA-treated patients. Monitor hepatic function prior to initiation and prior to each dose. Institute dose modifications or permanently discontinue as appropriate.
KADCYLA may lead to reductions in left ventricular ejection fraction (LVEF). Assess LVEF prior to initiation. Monitor and withhold dosing or discontinue as appropriate.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Interactions
Some medicines can increase exposure to DM1, the cell-killing component of KADCYLA, and may increase its harmful effects. These include strong inhibitors of the enzyme CYP3A4, such as ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, atazanavir, indinavir, nelfinavir, ritonavir, saquinavir and nefazodone. Tell your doctor if you take any of these medicines. Their use with KADCYLA should be avoided. Your doctor may choose an alternative medicine or delay KADCYLA treatment. If the combination cannot be avoided and treatment cannot be delayed, close monitoring for side effects is needed. No formal drug interaction studies have been conducted with KADCYLA.
Using KADCYLA
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label KADCYLA (ADO-TRASTUZUMAB EMTANSINE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GENENTECH, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00